New data at ERS showcases Sanofi's scientific leadership in addressing unmet needs across a variety of respiratory conditions

Presentations include data from the Dupixent (dupilumab) COPD and asthma pivotal trial programs, and data evaluating the role of Xenpozyme (olipudase alfa) in treating interstitial lung disease. i. Results from the Dupixent Phase III trial (BOREAS), showing significant improvements in annualized rate of exacerbations, lung function, quality of life, as well as symptoms of chronic obstructive pulmonary disease (COPD) and a new analysis showing reduced systemic corticosteroid use in adults with uncontrolled COPD with evidence of type 2 inflammation, will be presented as an oral presentation during the New England Journal of Medicine NEJM/ERS journal session and as a late breaking abstract.

Additionally, new data from a Phase III trial in children aged 6 to 11 years with moderate-to-severe asthma (VOYAGE) show Dupixent reduced systemic corticosteroid use related to exacerbations compared to placebo regardless of prior exacerbation history. The safety results of the COPD and asthma trials were generally consistent with the known safety profile of Dupixent in its approved respiratory indications.

Data from Sanofi’s Phase 1b study of SAR443765 in adults with asthma also demonstrate proof-of-mechanism, the first report of a novel biologic targeting both the thymic stromal lymphopoietin (TSLP) and interleukin-13 (IL-13) pathways.